Who should pay for the continuity of post-trial health care treatments?

Who should pay for the continuity of post-trial health care treatments?

Abstract Background The bioethical debate in the world on who should pay for the continuity of post-trials treatment of patients that have medical indication remains obscure and introduces uncertainties to the patients involved in the trials. The continuity of post-trial treatment was only incorpora...

Full description

Bibliographic Details
Main Authors: Roberto Iunes, Manuela Villar Uribe, Janet Bonilla Torres, Marina Morgado Garcia, Juliana Alvares-Teodoro, Francisco de Assis Acurcio, Augusto Afonso Guerra Junior
Format: Article
Language:English
Published: BMC 2019-06-01
Series:International Journal for Equity in Health
Subjects:
Equity
Treatment of patients
Post-trial access
Online Access:http://link.springer.com/article/10.1186/s12939-019-0919-0

Internet

http://link.springer.com/article/10.1186/s12939-019-0919-0

Similar Items